CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

US RESEARCH ROUNDUP-Amgen, Carmax, Pfizer

By Reuters News

Nov 4 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several US-listed companies, including Amgen, Carmax and Pfizer, on Wednesday.

HIGHLIGHTS

* Amgen Inc AMGN.O: Leerink Partners raises target price to $464 from $395

* Carmax Inc KMX.N: JP Morgan cuts target price to $65 from $70

* Pfizer PFE.N: Morgan Stanley cuts target price to $26 from $28

* Supernus SUPN.O: Piper Sandler resumes coverage with overweight rating; PT $47

* Yum Brands YUM.N: TD Cowen raises target price to $180 from $177

Following is a summary of research actions on US companies reported by Reuters on Wednesday. Stock entries are in alphabetical order.

* Adm ADM.N: JP Morgan raises to neutral from underweight

* Adtran Holdings Inc ADTN.O: Needham cuts target price to $9 from $14

* Advanced Micro Devices AMD.O: HSBC raises target price to $540 from $500

* Advanced Micro Devices AMD.O: JP Morgan raises target price to $575 from $550

* Advanced Micro Devices AMD.O: Morgan Stanley raises PT to $550 from $510

* Advanced Micro Devices AMD.O: Piper Sandler raises target price to $650 from $600

* Advanced Micro Devices AMD.O: Raymond James raises PT to $649 from $641

* Ametek AME.N: RBC raises target price to $308 from $291

* Amgen Inc AMGN.O: Canaccord Genuity raises target price to $440 from $384

* Amgen Inc AMGN.O: JP Morgan raises target price to $425 from $350

* Amgen Inc AMGN.O: Leerink Partners raises target price to $464 from $395

* Amgen Inc AMGN.O: Morgan Stanley raises target price to $410 from $359

* Amgen Inc AMGN.O: Oppenheimer raises target price to $520 from $480

* Amgen Inc AMGN.O: RBC raises target price to $470 from $430

* Amgen Inc AMGN.O: Scotiabank raises target price to $530 from $500

* Amgen Inc AMGN.O: TD Cowen raises target price to $531 from $452

* Amgen Inc AMGN.O: Truist Securities raises target price to $398 from $380

* Amneal pharma AMRX.O: JP Morgan raises target price to $25 from $24

* Amneal pharma AMRX.O: Leerink Partners raises target price to $25 from $23

* Apollo APO.N: JP Morgan raises target price to $157 from $153

* Apollo APO.N: KBW cuts target price to $130 from $135

* Apollo APO.N: RBC cuts target price to $138 from $146

* Arista Networks ANET.N: JP Morgan raises target price to $270 from $250

* Arvinas ARVN.O: Leerink Partners cuts target price to $8 from $9

* Astera Labs ALAB.O: Jefferies cuts target price to $350 from $450

* Astera Labs ALAB.O: Susquehanna cuts target price to $258 from $310

* Astera Labs ALAB.O: TD Cowen cuts target price to $225 from $300

* Atlas Energy Solutions AESI.N: Piper Sandler cuts target price to $13 from $15

* Atricure ATRC.O: Canaccord Genuity raises target price to $67 from $55

* Atricure ATRC.O: JP Morgan raises target price to $62 from $36

* Atricure ATRC.O: Piper Sandler raises target price to $70 from $60

* Autonation AN.N: JP Morgan cuts to neutral from overweight

* Ball Corp BALL.N: JP Morgan cuts to neutral from overweight

* Biomarin Pharmaceutical BMRN.O: JP Morgan cuts target price to $86 from $87

* Block XYZ.N: Raymond James raises target price to $100 from $97

* Block XYZ.N: RBC raises target price to $103 from $95

* Block XYZ.N: Scotiabank raises target price to $89 from $82

* Block XYZ.N: Susquehanna raises target price to $110 from $100

* Booking Holdings BKNG.O: B. Riley cuts target price to $265 from $274

* Booking Holdings BKNG.O: HSBC cuts target price to $240 from $301

* Booking Holdings BKNG.O: JP Morgan cuts target price to $205 from $248

* Booking Holdings BKNG.O: Piper Sandler cuts target price to $200 from $215

* Booking Holdings BKNG.O: RBC cuts target price to $205 from $220

* Broadridge Financial Solutions BR.N: Raymond James cuts PT to $230 from $240

* Broadridge Financial Solutions Inc BR.N: JP Morgan raises PT to $201 from $191

* Calix CALX.N: JP Morgan cuts target price to $50 from $58

* Carmax Inc KMX.N: JP Morgan cuts target price to $65 from $70

* Celanese Corp CE.N: JP Morgan raises target price to $77 from $76

* Ceribell CBLL.O: Canaccord Genuity raises target price to $33 from $26

* Coastal Financial Corp (Everett) CCB.O: Stephens raises PT to $60 from $54

* Columbus Mckinnon Corp CMCO.O: JP Morgan raises PT to $30 from $29

* Corcept Therapeutics CORT.O: Piper Sandler ups PT to $173 from $165

* Crown Holdings Inc CCK.N: JP Morgan cuts to neutral from overweight

* Cullinan Therapeutics CGEM.O: Guggenheim assumes coverage with buy rating

* Cullinan Therapeutics CGEM.O: Guggenheim assumes coverage with PT $35

* Digitalocean Holdings DOCN.N: Baird cuts target price to $130 from $165

* Digitalocean Holdings DOCN.N: Barclays cuts target price to $140 from $161

* Digitalocean Holdings DOCN.N: Canaccord Genuity cuts PT to $180 from $200

* Driven Brands Holdings DRVN.O: Canaccord Genuity cuts PT to $12 from $18

* Driven Brands Holdings DRVN.O: Canaccord Genuity cuts to hold from buy

* Dt Midstream DTM.N: JP Morgan cuts target price to $142 from $144

* Dynatrace Inc DT.N: Needham cuts target price to $65 from $68

* Dynatrace Inc DT.N: RBC cuts target price to $68 from $73

* Eastman Chemical Co EMN.N: RBC raises target price to $70 from $65

* Edwards Lifesciences Corp EW.N: Truist Securities raises to buy from hold

* Edwards Lifesciences Corp EW.N: Truist Securities ups PT to $113 from $95

* Enpro NPO.N: JP Morgan raises target price to $440 from $430

* Everest Group Ltd EG.N: KBW raises target price to $450 from $407

* Evertec Inc EVTC.N: KBW raises target price to $42 from $38

* Expeditors International of Washington EXPD.N: JP Morgan ups PT to $220 from $214

* Expeditors International of Washington EXPD.N: Stephens ups PT to $240 from $220

* Expro Group Holdings NV XPRO.N: Piper Sandler cuts target price to $15 from $16

* Faeth Therapeutics Inc FTH.O: Guggenheim cuts target price to $69 from $70

* Finwise Bancorp FINW.O: Stephens raises target price to $16 from $14

* First Bank (Hamilton) FRBA.O: Piper Sandler raises target price to $23 from $20

* Fiserv Inc FISV.O: JP Morgan raises target price to $65 from $60

* Fiserv Inc FISV.O: KBW raises target price to $70 from $60

* Fiserv Inc FISV.O: RBC raises target price to $70 from $65

* Fiserv Inc FISV.O: TD Cowen raises target price to $59 from $49

* Flywire Corp FLYW.O: JP Morgan raises target price to $23 from $20

* Fortune Brands Innovations FBIN.N: Truist Securities cuts PT to $60 from $70

* Freshworks FRSH.O: Baird raises target price to $15 from $13

* Freshworks FRSH.O: Canaccord Genuity raises target price to $17 from $15

* Gartner IT.N: Jefferies raises target price to $197 from $190

* Graphic Packaging Holding Company GPK.N: JP Morgan ups PT to $12 from $11.5

* Group 1 Automotive Inc GPI.N: JP Morgan cuts target price to $250 from $255

* Group 1 Automotive Inc GPI.N: JP Morgan cuts to underweight from neutral

* Hamilton Lane Incorporated HLNE.O: JP Morgan cuts target price to $144 from $150

* Hamilton Lane Incorporated HLNE.O: KBW raises PT to $120 from $116

* Healthstream HSTM.O: Canaccord Genuity raises target price to $32 from $29

* Ideaya Biosciences IDYA.O: Guggenheim cuts target price to $52 from $57

* Ideaya Biosciences IDYA.O: Leerink Partners cuts target price to $30 from $31

* Ideaya Biosciences IDYA.O: RBC cuts target price to $45 from $48

* Ideaya Biosciences IDYA.O: Truist Securities cuts target price to $57 from $59

* Incyte INCY.O: Leerink Partners cuts target price to $150 from $154

* Innovative Industrial Properties Inc IIPR.N: Piper Sandler raises PT to $46 from $44

* IPG Photonics Corp IPGP.O: Needham cuts target price to $105 from $120

* Keurig DR Pepper Inc KDP.O: JP Morgan raises target price to $41 from $39

* Keurig DR Pepper Inc KDP.O: Piper Sandler raises target price to $41 from $38

* Lendingtree TREE.O: JP Morgan cuts target price to $40 from $48

* Madrigal Pharmaceuticals MDGL.O: Canaccord Genuity ups PT to $633 from $612

* Madrigal Pharmaceuticals MDGL.O: Truist Securities ups PT to $743 from $709

* Mirum Pharmaceuticals MIRM.O: Leerink Partners cuts PT to $140 from $154

* Mvb Financial Corp MVBF.O: KBW cuts target price to $31 from $34

* Neutron Holdings Inc LIME.O: JP Morgan cuts target price to $33 from $38

* Nucor Corp NUE.N: Keybanc raises target price to $301 from $286

* Nurix Therapeutics NRIX.O: Jefferies cuts target price to $36 from $45

* People Incorporated PPLI.O: Piper Sandler cuts target price to $43 from $48

* Pershing Square Inc PS.N: RBC raises target price to $45 from $44

* Pfizer PFE.N: Morgan Stanley cuts target price to $26 from $28

* Pfizer PFE.N: RBC raises target price to $28 from $25

* PJT Partners PJT.N: KBW cuts target price to $155 from $159

* Procore Technologies Inc PCOR.N: JP Morgan raises PT to $74 from $69

* Red Rock Resorts RRR.O: JP Morgan cuts target price to $64 from $71

* Revolve Group RVLV.N: Piper Sandler cuts target price to $26 from $30

* Revvity RVTY.N: JP Morgan raises target price to $160 from $155

* Revvity RVTY.N: Leerink Partners raises target price to $180 from $160

* Revvity RVTY.N: RBC raises target price to $172 from $135

* Revvity RVTY.N: TD Cowen raises target price to $185 from $175

* Rhythm Pharmaceuticals RYTM.O: Needham cuts PT to $114 from $130

* River City Bank RCBC.O: KBW raises target price to $64 from $58

* Rxsight RXST.O: Piper Sandler cuts target price to $8 from $10

* Ryman Hospitality Properties Inc RHP.N: JP Morgan raises PT to $143 from $138

* Safehold Inc SAFE.N: RBC cuts target price to $12 from $13

* Skyworks Solutions SWKS.O: TD Cowen raises target price to $75 from $65

* Sonic Automotive Inc SAH.N: JP Morgan cuts target price to $58 from $63

* Sotera Health Company SHC.O: Piper Sandler cuts target price to $24 from $25

* Sprout Social SPT.O: Baird raises target price to $12 from $9

* Starwood Property Trust STWD.N: KBW cuts PT to $15 from $16

* Supernus SUPN.O: Piper Sandler resumes coverage with overweight rating; PT $47

* Talen Energy Corp TLN.O: CIBC raises target price to $515 from $493

* Tempus Ai TEM.O: Piper Sandler raises target price to $95 from $76

* the Williams Companies WMB.N: Raymond James raises PT to $86 from $85

* Travere Therapeutics TVTX.O: Guggenheim cuts target price to $78 from $89

* Ul Solutions Inc ULS.N: Jefferies cuts target price to $110 from $120

* Ultragenyx Pharmaceutical RARE.O: Canaccord Genuity cuts PT to $34 from $39

* Upstart Holdings UPST.O: Needham cuts target price to $30 from $42

* Upstart Holdings UPST.O: Piper Sandler cuts target price to $35 from $51

* Versant Media Group Inc VSNT.O: JP Morgan raises target price to $39 from $43

* Waters Corp WAT.N: JP Morgan raises target price to $470 from $435

* Waters Corp WAT.N: Leerink Partners raises target price to $500 from $450

* Waters Corp WAT.N: RBC raises target price to $525 from $475

* Xometry XMTR.O: JP Morgan raises target price to $140 from $120

* Xometry XMTR.O: RBC raises target price to $117 from $100

* Xplr Infrastructure LP XIFR.N: RBC cuts target price to $12 from $14

* Yum Brands YUM.N: RBC raises target price to $180 from $170

* Yum Brands YUM.N: TD Cowen raises target price to $180 from $177

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.